178 related articles for article (PubMed ID: 37313228)
1. Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.
Harlin M; Chepke C; Larsen F; Bell Lynum KS; Chumki SR; Fitzgerald H; Such P; Madera-McDonough J; Yildirim M; Panni M; Saklad SR
Neuropsychiatr Dis Treat; 2023; 19():1409-1416. PubMed ID: 37313228
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
Samalin L; Boudieu L; Llorca PM
Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
McIntyre RS; Such P; Yildirim M; Madera-McDonough J; Zhang Z; Larsen F; Harlin M
Curr Med Res Opin; 2023 Jul; 39(7):1021-1030. PubMed ID: 37272079
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study.
Citrome L; Such P; Yildirim M; Madera-McDonough J; Beckham C; Zhang Z; Larsen F; Harlin M
J Clin Psychiatry; 2023 Sep; 84(5):. PubMed ID: 37672016
[No Abstract] [Full Text] [Related]
7. Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole.
Salzman PM; Raoufinia A; Legacy S; Such P; Eramo A
Neuropsychiatr Dis Treat; 2017; 13():1125-1129. PubMed ID: 28461748
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole Lauroxil: A Review in Schizophrenia.
Frampton JE
Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy.
Baune BT
Curr Med Res Opin; 2024 Jan; 40(1):87-96. PubMed ID: 37999650
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
15. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal
Hard ML; Wehr A; von Moltke L; Du Y; Farwick S; Walling DP; Sonnenberg J
Ther Adv Psychopharmacol; 2019; 9():2045125319859964. PubMed ID: 31308935
[TBL] [Abstract][Full Text] [Related]
17. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
18. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.
Lauriello J; Weiden PJ; Gleeson CD; Shah A; Boulanger L; Jariwala-Parikh K; Hedgeman E; O'Sullivan AK
CNS Drugs; 2021 Oct; 35(10):1123-1135. PubMed ID: 34546558
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
[TBL] [Abstract][Full Text] [Related]
20. Initiation of aripiprazole once-monthly in patients with schizophrenia.
Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
